AEON Biopharma (AEON) Preferred Stock Liabilities (2021 - 2023)
AEON Biopharma (AEON) posted Preferred Stock Liabilities of $21.2 million for Q2 2023, up 0.96% sequentially from $21.0 million in Q1 2023, and down 92.32% YoY from $276.1 million in Q2 2022.
AEON Biopharma (AEON) Preferred Stock Liabilities (2021 - 2023) Analysis & Trends
AEON Biopharma has reported Preferred Stock Liabilities for 3 years, with the latest figure at $21.2 million in Q2 2023.
- Quarterly Preferred Stock Liabilities fell 92.32% year-over-year to $21.2 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $21.2 million (down 92.32% YoY) and the FY2022 annual result came in at $278.5 million, up 0.9% from the prior year.
- Preferred Stock Liabilities rose to $21.2 million in Q2 2023 per AEON's latest filing, from $21.0 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $278.5 million in Q4 2022 and troughed at $21.0 million in Q1 2023.
- A 3-year average of $200.5 million and a median of $276.0 million in 2021 frame the typical range for Preferred Stock Liabilities.
- The sharpest annual moves came in 2022 and 2023: Preferred Stock Liabilities jumped 891.78% in 2022, then plunged 92.39% in 2023.
- Over 3 years, Preferred Stock Liabilities stood at $276.0 million in 2021, then gained by 0.9% to $278.5 million in 2022, then tumbled by 92.39% to $21.2 million in 2023.
- According to Business Quant data, Preferred Stock Liabilities over the past three periods registered $21.2 million, $21.0 million, and $278.5 million for Q2 2023, Q1 2023, and Q4 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | AEON Biopharma | 9.71 Mn | 6.28 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 21.19 Mn |
| Mar 31, 2023 | 20.99 Mn |
| Dec 31, 2022 | 278.49 Mn |
| Sep 30, 2022 | 276.90 Mn |
| Jun 30, 2022 | 276.08 Mn |
| Mar 31, 2022 | 276.00 Mn |
| Dec 31, 2021 | 276.00 Mn |
| Sep 30, 2021 | 276.00 Mn |
| Jun 30, 2021 | 27.84 Mn |
| Mar 31, 2021 | 276.00 Mn |